Abstract
Tumor lysis syndrome (TLS) is a serious complication in patients with hematological malignancies. Massive lysis of tumor cells can lead to hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcaemia. These metabolic disturbances may result in renal failure, because of precipitation of uric acid crystals and calcium phosphate salts in the kidney. The standard prophylaxis or treatment of hyperuricemia consists of decreasing uric acid production with allopurinol and facilitating its excretion by urinary alkalinization and hyperhydration. By inhibiting the enzyme xanthine oxidase, allopurinol blocks the conversion of hypoxanthine and xanthine into uric acid. An alternative treatment is urate oxidase which oxidates uric acid into allantoin. Allantoin is 5 - 10 times more soluble than uric acid and is therefore excreted easily. In several clinical trials rasburicase, the recombinant form of urate oxidase, has shown to be very effective in preventing and treating hyperuricemia. Rasburicase, in contrast with the non-recombinant form of urate oxidase uricozyme, is associated with a low incidence of hypersensitivity reactions. In addition to the demonstrated clinical benefit, rasburicase also proved to be a cost-effective option in the management of hyperuricemia.
| Original language | English |
|---|---|
| Pages (from-to) | 1431-1440 |
| Number of pages | 10 |
| Journal | Nucleosides nucleotides & nucleic acids |
| Volume | 23 |
| Issue number | 8-9 |
| DOIs | |
| Publication status | Published - Oct 2004 |
| Event | Joint 11th International and 9th European Symposium on Purines and Pyrimidines in Man - Egmond Aan Zee, Netherlands Duration: 9 Jun 2003 → 13 Jun 2003 |
Keywords
- rasburicase
- tumor lysis
- hematological malignancies
- TUMOR-LYSIS-SYNDROME
- RECOMBINANT URATE OXIDASE
- MALIGNANCY-ASSOCIATED HYPERURICEMIA
- LYMPHOMA
- LEUKEMIA
- CHILDREN
- PROPHYLAXIS
- EXPERIENCE
- PREVENTION